Found: 119
Select item for more details and to access through your institution.
Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1395378
- By:
- Publication type:
- Article
Suppression of exosomal hsa_circ_0001005 eliminates the Vemurafenib resistance of melanoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 5921, doi. 10.1007/s00432-022-04434-y
- By:
- Publication type:
- Article
ATP-柠檬酸裂解酶在黑素瘤维罗非尼治疗抵抗中的作用机制研究.
- Published in:
- Progress in Modern Biomedicine, 2020, v. 20, n. 1, p. 30, doi. 10.13241/j.cnki.pmb.2020.01.006
- By:
- Publication type:
- Article
Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady‐State Pharmacokinetics of Vemurafenib in Patients With BRAF<sup>V600</sup> Mutation–Positive Malignancies.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 1, p. 39, doi. 10.1002/cpdd.822
- By:
- Publication type:
- Article
Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF<sup>V600</sup> Mutation–Positive Malignancies.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 651, doi. 10.1002/cpdd.788
- By:
- Publication type:
- Article
Absolute Bioavailability of Vemurafenib in Patients With BRAF<sup>V600</sup> Mutation–Positive Malignancies.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 4, p. 496, doi. 10.1002/cpdd.773
- By:
- Publication type:
- Article
Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAF<sup>V600</sup> Mutation–Positive Metastatic Malignancy.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 6, p. 837, doi. 10.1002/cpdd.643
- By:
- Publication type:
- Article
RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 01, doi. 10.3389/fphar.2022.950571
- By:
- Publication type:
- Article
Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.906043
- By:
- Publication type:
- Article
Vemurafenib Inhibits Enterovirus A71 Genome Replication and Virus Assembly.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 9, p. N.PAG, doi. 10.3390/ph15091067
- By:
- Publication type:
- Article
Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program.
- Published in:
- Journal of Oncology, 2019, p. 1, doi. 10.1155/2019/1697913
- By:
- Publication type:
- Article
NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib.
- Published in:
- Journal of Cutaneous Pathology, 2019, v. 46, n. 3, p. 190, doi. 10.1111/cup.13401
- By:
- Publication type:
- Article
Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
- Published in:
- Biology Direct, 2024, v. 19, n. 1, p. 1, doi. 10.1186/s13062-023-00451-0
- By:
- Publication type:
- Article
Resistance mechanism of the oncogenic β3‐αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.
- Published in:
- Chemical Biology & Drug Design, 2019, v. 93, n. 2, p. 177, doi. 10.1111/cbdd.13399
- By:
- Publication type:
- Article
Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 3, p. 1963, doi. 10.3390/ijms24031963
- By:
- Publication type:
- Article
SK119, a Novel Shikonin Derivative, Leads to Apoptosis in Melanoma Cell Lines and Exhibits Synergistic Effects with Vemurafenib and Cobimetinib.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 10, p. 5684, doi. 10.3390/ijms23105684
- By:
- Publication type:
- Article
BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 21, p. 11951, doi. 10.3390/ijms222111951
- By:
- Publication type:
- Article
The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 19, p. 10767, doi. 10.3390/ijms221910767
- By:
- Publication type:
- Article
Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 12, p. 6174, doi. 10.3390/ijms22126174
- By:
- Publication type:
- Article
Preclinical Evaluation of Vemurafenib as Therapy for BRAF<sup>V600E</sup> Mutated Sarcomas.
- Published in:
- International Journal of Molecular Sciences, 2018, v. 19, n. 4, p. 969, doi. 10.3390/ijms19040969
- By:
- Publication type:
- Article
Erdheim-Chester Disease With BRAF V600E Mutation and Central Diabetes Insipidus Successfully Treated With Glucocorticoid.
- Published in:
- JCEM Case Reports, 2023, v. 1, n. 2, p. 1, doi. 10.1210/jcemcr/luad014
- By:
- Publication type:
- Article
Rapid exacerbation of malignant melanoma during short‐term discontinuation of vemurafenib.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells.
- Published in:
- Metabolites (2218-1989), 2021, v. 11, n. 11, p. 777, doi. 10.3390/metabo11110777
- By:
- Publication type:
- Article
Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1182853
- By:
- Publication type:
- Article
Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing BRAF<sup>V600E</sup>Mutated Erdheim-Chester Disease: A Case Report.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Utilization of solid in oil nanodispersion to prepare a topical vemurafenib as potential delivery system for skin melanoma.
- Published in:
- Applied Nanoscience, 2023, v. 13, n. 4, p. 2845, doi. 10.1007/s13204-021-02158-y
- By:
- Publication type:
- Article
Neurodegeneration in patients with multisystem Langerhans cell histiocytosis treated with vemurafenib.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 6, p. 2508, doi. 10.1111/bjh.19483
- By:
- Publication type:
- Article
Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF<sup>V600E</sup>-Mutant CRC: A Case Report and Review.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.795381
- By:
- Publication type:
- Article
Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib.
- Published in:
- Advances in Dermatology & Allergology / Postępy Dermatologii i Alergologii, 2018, v. 35, n. 1, p. 39, doi. 10.5114/ada.2018.73163
- By:
- Publication type:
- Article
Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib.
- Published in:
- Advances in Dermatology & Allergology / Postępy Dermatologii i Alergologii, 2018, v. 35, n. 1, p. 39, doi. 10.5114/ada.2018.73163
- By:
- Publication type:
- Article
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-45798-8
- By:
- Publication type:
- Article
BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Pulmonary Erdheim-Chester disease successfully treated with vemurafenib.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 2, p. 673, doi. 10.1007/s00277-023-05534-6
- By:
- Publication type:
- Article
Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah's Witness patient.
- Published in:
- 2022
- By:
- Publication type:
- Letter
PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.
- Published in:
- Cell Communication & Signaling, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12964-022-00989-y
- By:
- Publication type:
- Article
PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.
- Published in:
- Cell Communication & Signaling, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12964-022-00989-y
- By:
- Publication type:
- Article
Direct structure determination of vemurafenib polymorphism from compact spherulites using 3D electron diffraction.
- Published in:
- Communications Chemistry, 2023, v. 6, n. 1, p. 1, doi. 10.1038/s42004-022-00804-2
- By:
- Publication type:
- Article
Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 13, p. 2800, doi. 10.3390/jcm10132800
- By:
- Publication type:
- Article
Novel Anti-Melanoma Compounds Are Efficacious in A375 Cell Line Xenograft Melanoma Model in Nude Mice.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 9, p. 1276, doi. 10.3390/biom13091276
- By:
- Publication type:
- Article
Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based study.
- Published in:
- British Journal of Clinical Pharmacology, 2023, v. 89, n. 4, p. 1338, doi. 10.1111/bcp.15576
- By:
- Publication type:
- Article
Granulomatous tattoo reaction associated with BRAF/MEK inhibitor therapy for metastatic melanoma.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 11, p. 1630, doi. 10.1111/ijd.17273
- By:
- Publication type:
- Article
Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.
- Published in:
- Thyroid, 2022, v. 32, n. 3, p. 273, doi. 10.1089/thy.2021.0565
- By:
- Publication type:
- Article
A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?
- Published in:
- International Journal of Rheumatic Diseases, 2017, v. 20, n. 3, p. 398, doi. 10.1111/1756-185X.12396
- By:
- Publication type:
- Article
In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors.
- Published in:
- Molecules, 2023, v. 28, n. 13, p. 5273, doi. 10.3390/molecules28135273
- By:
- Publication type:
- Article
Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines—An Isobolographic Analysis.
- Published in:
- Molecules, 2023, v. 28, n. 9, p. 3889, doi. 10.3390/molecules28093889
- By:
- Publication type:
- Article
Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4- b ]indol-3-one Derivatives as Potent Inhibitors of EGFR T790M /BRAF V600E Pathways.
- Published in:
- Molecules, 2023, v. 28, n. 3, p. 1269, doi. 10.3390/molecules28031269
- By:
- Publication type:
- Article
A Comprehensive In Silico Exploration of Pharmacological Properties, Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from Xylopia vielana Targeting B-Raf Kinase.
- Published in:
- Molecules, 2022, v. 27, n. 3, p. 917, doi. 10.3390/molecules27030917
- By:
- Publication type:
- Article
Proteome analysis of NRF2 inhibition in melanoma reveals CD44 up-regulation and increased apoptosis resistance upon vemurafenib treatment.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 4, p. 956, doi. 10.1002/cam4.4506
- By:
- Publication type:
- Article
SERPINB8 and furin regulate ITGAX expression and affect the proliferation and invasion of melanoma cells.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 1, p. 24, doi. 10.1111/exd.14677
- By:
- Publication type:
- Article
Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.827985
- By:
- Publication type:
- Article